HDAC6 and Alzheimer disease: As a proof that iPSC-derived organoids can be employed for the assessment of candidate drugs, recently, Choi and colleagues generated brain organoids from AD patient and HCs to evaluate the effect of a histone deacetylase 6 (HDAC6) inhibitor, CKD-504, on Tau pathology.